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Abstract
Background—Trials have demonstrated the efficacy of rigorous diet and physical activity 
promotion (D&PA) programs for adults at increased risk for type 2 diabetes to reduce diabetes 
incidence and improve measures of glycemia.
Purpose—To evaluate D&PA programs for individuals at increased risk for type 2 diabetes 
primarily to lower diabetes risk, lower body weight, and improve glycemia.
Data Sources—MEDLINE, Cochrane Central Register of Controlled Trials, CAB Abstracts, 
Global Health, and Ovid HealthStar from 1991 through 27 February 2015, with no language 
restriction.
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Study Selection—8 researchers screened articles for single group or comparative studies of 
combined D&PA programs with at least 2 sessions of at least 3 month duration in participants at 
increased risk for type 2 diabetes.
Data Extraction—7 researchers extracted data—on study design, participant, intervention, 
outcome descriptions, and results—and assessed study quality.
Data Synthesis—53 studies (30 D&PA vs. control, 13 more vs. less intensive, 13 in single 
programs) evaluated 66 programs. Compared with usual care, D&PA reduced type 2 diabetes 
incidence (RR = 0.59; 95% CI 0.51, 0.66; 16 studies), lowered body weight (net change = −2.2%; 
95% CI −2.9, −1.4; 24 studies) and fasting blood glucose (net change = −0.12 mmol/L; 95% CI 
−0.20, −0.05; 17 studies), and improved other cardiometabolic risk factors. There was limited 
evidence for clinical events. More intensive programs were more effective.
Limitations—The wide variation in D&PA programs limited identification of features most 
relevant to effectiveness. Evidence on clinical outcomes and in children was sparse.
Conclusions—Combined D&PA promotion programs are effective to decrease diabetes 
incidence and improve cardiometabolic risk factors for patients at increased risk. More intensive 
programs are more effective.
Primary Funding Source—Centers for Disease Control and Prevention Community Preventive 
Services Task Force.
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Diabetes is a large and growing medical problem and the costs to society are high and 
escalating. According to the latest figures from the Centers for Disease Control and 
Prevention (CDC), 29.1 million people or 9.3% of the U.S. population have diabetes and 1.7 
million new cases are diagnosed annually (1). Worldwide, it is estimated that 387 million 
adults are living with diabetes and this number is projected to increase to 592 million by 
2035 (2). Prevalence of diabetes and related costs are expected to more than double in the 
next quarter century (3), as more than 86 million Americans (37% of the adult population) 
are at risk of developing diabetes (1). Effective prevention strategies are, therefore, critically 
important to slow the diabetes tide and its associated burden.
Nearly 9 out of 10 new cases of diabetes are due to type 2 diabetes, whose natural history is 
characterized by a gradual rise in glycemia. Identifying those at increased risk can allow the 
implementation of interventions to lower the risk of progressing to clinical diabetes. The 
American Diabetes Association has defined pre-diabetes as a high-risk category, based on a 
level of glycemia that does not meet criteria for diabetes but is too high to be considered 
normal (4). People with pre-diabetes progress to type 2 diabetes at a rate of about 5–10% per 
year without any intervention (5). Three large clinical trials from the US (6), Finland (7), 
and China (8) have shown that the main components of diabetes prevention in adults are 
weight loss and increased physical activity. In these trials, among people at risk for type 2 
diabetes, rigorous application of combined diet and physical activity (D&PA) promotion 
programs, with the goals of weight loss and increased physical activity were successful at 
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reducing risk of diabetes by 50–60% during the active intervention period (3 to 6 years). 
Although attenuated, the effect of the intervention can persist long-term (9–11). The results 
of these trials are well known; however, wide-scale implementation in clinical and 
community-based settings has recently begun, but requires further progress (12).
Combined D&PA promotion programs aim to prevent type 2 diabetes among people who 
are at increased risk for the disease. These programs actively encourage people to improve 
their diet and increase their physical activity using trained providers in various settings who 
work with clients for at least 3 months, providing some combination of counseling, 
coaching, and extended support in multiple sessions related to diet and physical activity, 
delivered in-person, or by other methods. Programs may also include numerous other 
features, including specialized counselors, a range of number and frequency of sessions, 
different session types, and different diet, weight loss, or exercise goals.
The purpose of this review was to assess the effectiveness of D&PA promotion programs 
implemented in a wide range of clinical or community settings to reduce risk of new-onset 
diabetes among adults and children at risk for type 2 diabetes. The Community Preventive 
Services Task Force (Task Force, www.thecommunityguide.org) used this review to update 
its guidance in diabetes prevention and to identify current gaps in the evidence to inform 
future research. Potential effect modifiers such as intensity and specificity of the programs, 
settings and implementers were evaluated. Furthermore, the potential benefit of the diabetes 
prevention programs extending to other cardiometabolic risk factors, such as overweight, 
high cholesterol and high blood pressure, was also assessed.
Methods
The review was conducted in accordance with the methodology of the Task Force (13;14) 
and the highest standards for conducting systematic reviews (15;16). We convened a panel 
of domain experts and stakeholders (Coordination Team), which together with our 
Community Guide Technical Monitor and Task Force members provided input regarding the 
protocol, feedback on the findings, conclusions, and evidence gaps.
Data Sources
We searched MEDLINE, the Cochrane Central Register of Controlled Trials, CAB 
Abstracts, Global Health, and Ovid HealthStar from 1991 through 27 February 2015 with no 
language restrictions. Supplemental Table 1 shows the search strategy. We also screened 
through reference lists of related systematic and narrative reviews, and suggestions from the 
expert panel.
Study Selection
We included randomized controlled trials and prospective non-randomized comparative 
studies with at least 30 participants per group, and prospective single group intervention 
studies with at least 100 participants. The population of interest was focused on adults or 
children at increased risk for type 2 diabetes (i.e., with pre-diabetes) as determined by 
glycemia measures or diabetes risk assessment tools. We included studies of participants 
with metabolic syndrome (who are at increased risk of both diabetes and cardiovascular 
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disease) or whose participants were chosen because they were at risk for either type 2 
diabetes or cardiovascular disease. However, we excluded studies of participants with 
established type 2 diabetes or whose only risk factor was obesity or increased risk for 
cardiovascular disease (without explicit inclusion of participants with pre diabetes). The 
implied or explicit intent of the D&PA programs had to be to prevent diabetes and had to 
include at least 2 contact sessions (in-person or virtually) over a minimum period of 3 
months. Programs had to include both dietary and increased physical activity components 
and could be conducted in any outpatient setting. We allowed any type of advice to improve 
diet and increase physical activity (except single food or supplement dietary changes such as 
adding fish oil). We excluded interventions that included antidiabetic medications. The 
comparative studies had to include a usual care arm (no active D&PA program) or a lower-
intensity D&PA program (e.g., with fewer contact sessions or a more liberal diet). We 
required at least 6 month follow-up for any of the following outcomes: incident diabetes, 
reversion to normoglycemia, body weight, glycemia measures (fasting glucose [FG], 2 hour 
glucose after a 75-gram oral glucose tolerance test [2hG], hemoglobin A1c [HbA1c]), all-
cause death, diabetes-related clinical outcomes (e.g., cardiovascular events, end-stage renal 
disease, nephropathy, amputation, retinopathy, neuropathy, skin ulcers, periodontitis), blood 
pressure (BP), and lipids (total cholesterol, low and high density lipoprotein cholesterol 
[LDL, HDL], and triglycerides).
Data Extraction and Quality Assessment
We screened titles and abstracts using Abstrackr (17). Eight researchers double-screened the 
abstracts after iterative training of all reviewers on the same batches of abstracts. Discordant 
decisions and queries were resolved at group meetings. Full-text articles were retrieved for 
all potentially relevant abstracts and rescreened by the same researchers.
Each study was extracted by one of seven experienced methodologists and confirmed by a 
senior methodologist; the same methodologists assessed study quality. Data extraction was 
conducted in SRDR (18), and included elements for study design including eligibility 
criteria, population characteristics, detailed descriptions of the D&PA programs and 
comparison interventions, outcomes, and results. We assessed each study’s quality based on 
12 Community Guide quality of execution questions (Supplemental Table 2, footnotes) 
(14;19). Per Community Guide protocol, we excluded studies with “limited quality of 
execution,” defined as having at least five major limitations.
Data Synthesis and Analysis
All extracted data were tabulated into Summary Evidence Tables (available in the 
Supporting Materials at the URL listed at the beginning of the Results section). Because 
only two studies were conducted in children, we report these separately and do not include 
them in the meta-analyses. For outcomes with data from at least three comparative studies of 
D&PA vs. usual care, we performed profile likelihood random effects model meta-analysis 
of risk ratio (RR) or net change (20). For non-randomized studies, we preferentially used 
adjusted analysis results. Meta-analyses were conducted with the metaan package in Stata 
13.1 (StataCorp, College Station, TX). For the overall meta-analyses of incident diabetes 
and reversion to normoglycemia, we used the longest reported duration of follow-up data. 
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For continuous outcomes, we used the data closest to 1 year of follow-up, data restricted to 
<2 years of follow-up, and longest followup. We evaluated differences in effect (for incident 
diabetes and weight only) based on any direct comparisons of different D&PA programs 
within studies, any reported within-study subgroup analyses, and across-study random 
effects model metaregression across all D&PA programs based on predetermined study 
setting and D&PA program features. Incident diabetes and weight change were chosen for 
metaregression based on their relative importance in determining the effectiveness of D&PA 
programs. Metaregressions were conducted with the metareg package in Stata and were 
considered to be potentially significant if P<0.10. For each outcome with at least 10 studies, 
the possibility of publication bias was examined with funnel plots and the Harbord test for 
diabetes incidence and the Egger test for continuous outcomes using the metabias and 
metafunnel packages in Stata (21).
Role of the Funding Source
One member of the Coordination Team and our Technical Monitor are employed by the 
CDC; none of the Task Force members are. The Coordination Team, Technical Monitor, 
and members of the Community Preventive Services Task Force participated in formulating 
the study questions and developing the protocol but did not participate in the literature 
search, determination of study eligibility criteria, data analysis or interpretation. The 
Coordination Team, Technical Monitor, and CDC personnel were provided with an 
opportunity to provide feedback on the manuscript and the decision to submit the manuscript 
for publication, but the research team retained final determination of the content and 
decision to publish.
Results
Supplemental Figure 1 summarizes the search yield. Of 11,317 citations (plus articles from 
other existing systematic reviews and domain experts), 53 studies described 66 D&PA 
programs in 104 articles (6–11;22–119). One additional study was excluded for limited 
quality of execution (with six major limitations) (120). The included studies described 26 
randomized and 4 nonrandomized comparisons of D&PA programs versus usual care, 12 
randomized and 1 nonrandomized comparisons of two or more D&PA programs (3 of which 
also had usual care arms), and 13 single group studies of D&PA programs. Thirty-three 
studies were of good quality (0 to 1 limitation) and 20 were of fair quality (2 to 4 
limitations) (Supplemental Table 2). The most common limitations were poor descriptions 
of the study populations or intervention programs; problems with data measurement or 
interpretation; and high dropout rates. While half the studies (n=27) analyzed all enrolled 
participants, nine had more than 20% drop-out (or loss-to-follow-up) rates.
The characteristics of the D&PA programs are summarized in Table 1 (with details in 
(Supplemental Tables 3–5). All but five programs (in four studies) ran for at least 6 months. 
Programs offered a wide range of number of contact sessions (0 [virtual contacts only] to 72, 
median 15) and most programs included both a core period (with frequent contact sessions) 
and a maintenance period (when participants were contacted less frequently). With the 
exception of seven programs that were delivered entirely over the internet, by video, 
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telephone, or email, programs used in-person individual or group sessions, or both, on diet 
or exercise, or both. Sessions were led by different combinations of trained diet counselors 
including dietitians, nutritionists, or others; trained exercise counselors including physical 
trainers or others; nurses; physicians or psychologists; or trained laypeople. Many programs 
included specific weight loss, diet, or physical activity goals (Table 1). Some programs 
included individually tailored plans for diet and physical activity.
Table 2 summarizes the patient characteristics (with details in Supplemental Table 6). Thirty 
(57%) studies were restricted to participants with prediabetes, of which 21 studies used 
standard diagnostic criteria; 12 (23%) studies included only participants at increased risk of 
diabetes based on a risk score. More than three-quarters of studies included mostly 
overweight or obese participants and most study participants were female and at least 
middle-aged. Two studies were conducted in adolescents at increased risk of type 2 diabetes. 
These two studies are analyzed separately. None of the studies reported any long-term harms 
directly related to the D&PA programs.
Incident Diabetes
Sixteen studies that compared D&PA to usual care reported new-onset diabetes (6–9;22–
33); two studies compared two programs each to usual care. All but three were randomized 
trials (9;22;26). Incident diabetes was reported between 1 and 23 years from the start of the 
programs (Figure 1). Across studies, between 0% (at 1 year) and 73% (at 23 years) of 
participants in the D&PA programs developed diabetes. At all time points participants in the 
D&PA programs were less likely to develop diabetes. Across all studies, the summary RR 
for incident diabetes was 0.59 (95% CI 0.51, 0.66) with no statistical heterogeneity. The 
median risk difference across studies was −11 percentage points (IQI −16, −5). Funnel plot 
analysis did not find different effects between larger and smaller studies (Harbord test 
P=0.27).
Both the U.S. Diabetes Prevention Program (DPP) (6) and the Finnish Diabetes Prevention 
Study (DPS) (7) found statistically larger effects in older participants; but while DPS found 
a nonsignificant effect in the youngest age group (<51 years), DPP found statistically 
significant effects in all age groups. Neither study found differences by sex. The DPP found 
no difference by race or ethnicity and DPS found no difference by educational attainment. 
The Japan DPP study reported a significant effect of D&PA among participants with 
baseline HbA1c ≥5.7% in contrast with participants with lower baseline HbA1c, but they did 
not provide a statistical analysis of the difference between subgroups (34).
Comparing across studies, no significant differences were found by setting; number of 
sessions; program duration; whether the D&PA program was based on the DPP or DPS 
approach; inclusion of a weight loss goal, individual or group diet or exercise sessions 
(analyzed separately); or individually tailored diet plans, diet or exercise counselors 
(analyzed separately). The 11 programs that included an individually tailored exercise plan 
(RR 0.53; 95% CI 0.45, 0.63) had a possibly greater effect than the five that did not (RR 
0.67; 95% CI 0.55, 0.81; P for interaction=0.070).
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Six studies directly compared more versus less intensive D&PA programs 
(28;45;47;48;50;56). Compared with less intensive programs, more intensive programs had 
more sessions (four studies); weight loss, diet, or exercise goals (three studies), or—in one 
study each—a maintenance phase, more intensive diet and exercise plans, an exercise 
physiologist, individual contact sessions, or in-person (vs. DVD) sessions. All five studies 
that reported at least one case of incident diabetes found lower diabetes incidence with more 
intensive program (RR 0.28 to 0.56), but in only one study was this statistically significant 
(50) (Supplemental Figure 2).
Reversion to Normoglycemia
Six studies (five trials, one non-randomized study) that compared D&PA to usual care 
reported reversion to normoglycemia as early as 1 year from the start of the intervention 
(Figure 2) (6;22–25;32). Across studies, between 20% (at 2 years) and 52% (at 6 years) of 
participants in the D&PA programs reverted to normoglycemia. At 3 years (four studies) 
and across time points, the summary RR for achieving normoglycemia were statistically 
significant, with an overall summary RR of 1.53 (95% CI 1.26, 1.71), with no statistical 
heterogeneity. The median risk difference across studies was 12 percentage points (IQI 6, 
14). No within-study subgroup differences were reported and no between-study subgroup 
differences were found. Three studies directly compared more versus less intensive 
programs (45;47;48), all of which favored more intensive programs (RR 1.58 to 2.11), two 
of which were statistically significant (47:48) (Supplemental Figure 3).
Clinical events
Three long-term studies reported all-cause mortality, two of which also reported 
cardiovascular mortality with no consistent pattern of results. The Da Qing study reported 
lower risk for all-cause mortality (hazard ratio [HR] 0.71; 95% CI 0.51, 0.99) with D&PA 
after 23 years (10), but this effect was restricted to women and was not significant at earlier 
time points (HR 1.33 at 6 years and 0.96 at 20 years) (8). Knowler et al. (DPP) found no 
effect at 3 years (RD −0.6/1000 person-years) and Tuomilehto et al. (DPS) found no effect 
at 10 years (HR 0.57; 95% CI 0.21, 1.58) (6;105). Regarding cardiovascular death, neither 
Da Qing (HR 0.83; 95% CI 0.48, 1.40) at 20 years nor DPP (RR 0.50; 95% CI 0.09, 2.73) at 
3 years found significant effects (10; 105). The Da Qing study reported a reduction in severe 
retinopathy (HR 0.53; 95% CI 0.29, 0.99) (71). Limited evidence found no significance for 
other clinical outcomes (cardiovascular events [2 studies], nephropathy, neuropathy, and 
retinopathy [1 study each]), often due to lack of power.
Body weight and glycemia
The 24 studies that compared D&PA programs to usual care and reported weight change all 
found net weight loss with D&PA programs (6;7;9;22–24;27–33;35–4152–55), ranging 
from −0.2% to −10.5% of initial body weight (summary net change −2.2%; 95% CI −2.9, 
−1.4); however, the studies were highly statistically heterogeneous (I2 = 89%, PHeterogeneity 
<0.001) (Figure 3). Funnel plot analysis did not find different effects between larger and 
smaller studies (Egger test P=0.51). By meta-regression, we tested the same covariables 
examined for Incident Diabetes and the only variable for which there were different effects 
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across studies was for program based on DPP or DPS. The 12 programs based on DPP or 
DPS yielded a net change of −3.0% (95% CI −4.1, −1.9) compared with the 13 other 
programs (net change −1.6%; 95% CI −2.5, −0.6; P = 0.051 for interaction). However, 
heterogeneity across studies remained high (residual I2=95%). Across all 42 D&PA 
programs (not compared with usual care) (6;7;22;23;27–33;35–51;54–58), none of the 
factors explored by meta-regression yielded statistically significant differences across 
studies. In contrast to the across-studies analysis, six of the nine studies that directly 
compared more versus less intensive D&PA programs found statistically significant greater 
weight loss with the more intensive programs (28;44;45;47–50;56;58) (Supplemental Figure 
4).
Eighteen studies that compared D&PA programs to usual care reported glycemia outcomes 
(6–9;23;28–32;35–40;52;53). Overall, D&PA programs improved measures of glycemia. 
Across studies, at follow-up durations closest to 1 year, FG improved with a summary net 
change of −0.12 mmol/L (95% CI −0.20, −0.05; 17 studies; I2 =77%) (−2.2 mg/dL; 95% CI 
−3.6, −0.9), 2hG improved by −0.48 mmol/L (95% CI −0.86, −0.17; 11 studies; I2 =87%) 
(−8.6 mg/dL (95% CI −15.5, −3.1), and HbA1c improved by −0.08% (95% CI −0.12, −0.04; 
8 studies; I2 = 0%) (Supplemental Table 7). Funnel plot analysis found no significant small 
study effect with FG (Egger test P=0.54), but smaller studies were more likely to have large 
net reductions in 2hG (P=0.003); however, studies reporting significant effects on FG were 
no more likely to report 2hG results than those with nonsignificant FG effects (P=0.21). 
Across eight studies that compared more versus less intensive D&PA programs (28;43–
45;48–50;56) (Supplemental Table 8), the median net change in FG was −0.11 mmol/L (full 
range −0.20, 0.17) (−2.0 mg/dL; full range −3.6, 1.8), favoring more intensive programs; 
however, in only one study was the difference statistically significant (56). Four studies 
found a median net change of −0.37 mmol/L (full range −0.6, −0.2) (−6.7 mg/dL; full range 
−11, −3.6) in 2hG, favoring more intensive programs (44;45;48;50); in two studies the 
difference was significant (48;50). None of these studies reported on HbA1c.
Across the 31 D&PA programs (not compared with usual care) in 24 studies that reported 
FG (6–9;23;28–32;36–39;43–46;48–50;52;53;56), there were differences based on whether 
individual diet sessions and diet counselors were included. Adjusting for follow-up duration, 
programs with individual diet sessions (n=25/31) or with diet counselors (n=22/31) yielded 
larger decrements in FG (individual sessions: −0.24 vs. −0.02 mmol/L [−4.3 vs. −0.4 mg/
dL], P=0.020; counselors: −0.25 vs. −0.07 mmol/L [−4.5 vs. −1.3 mg/dL; P=0.034).
Blood pressure and lipids
Across 17 studies comparing D&PA programs to usual care (6;7;9;22;23;28;29;32;33;35–
39;52–54), at follow-up durations closest to 1 year, D&PA improved BP (systolic: net 
change = −1.6 mmHg; 95% CI −2.7, −0.5; I2 = 45%) (diastolic: net change = −1.6 mmHg; 
95% CI −2.5, −0.8; I2 =73%) (Supplemental Table 9). No evidence of small study effects 
was found (Egger test = 0.51 systolic, 0.83 diastolic) Across 14 studies, D&PA also 
statistically significantly improved lipid levels (7;9;22;23;28;29;33;35–39;52;53): total 
cholesterol (net change = −0.05 mmol/L; 95% CI −0.12, −0.002 [−1.8 mg/dL (95% CI −4.6, 
−0.1]; 12 studies; I2 = 0%), LDL (net change = −0.09 mmol/dL; 95% CI −0.17, −0.01 [−3.3 
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mg/dL; 95% CI −6.4, −0.3]; 8 studies; I2 = 0%), HDL (net change = 0.03 mmol/L; 95% CI 
0.02, 0.05 [1.2 mg/dL; 95% CI 0.7, 1.7]; 12 studies; I2 = 0%), and triglycerides (net change 
= −0.07 mmol/L; 95% CI −0.14, −0.02 [−6.5 mg/dL; 95% CI −12.7, −1.8; 13 studies; I2 
=38%) (Supplemental Table 10). No evidence of small study effects was found (Egger test = 
0.17 total cholesterol, 0.75 HDL, 0.12 triglycerides).
Virtual programs
Five studies evaluated programs that were conducted via web-tools, social networking, 
email, text messaging, video, or a combination of these, with no in-person sessions 
(28;33;41;42;88). One study (28) found smaller, but still significant improvements in weight 
and FG with a DVD compared with an in-person program: weight −5% vs. −7% from 
baseline; FG −2.7 versus −4.2 mg/dL. Two studies (41;42) found similar effects on weight 
loss as found in studies with in-person sessions: −3% to −5% from baseline. One study in 
India (33) found that an intervention relying on text messages was effective compared to 
usual care, with lesser diabetes incidence over 2 years (18% vs. 27%; HR=0.64; 95% CI 
0.45, 0.92) with statistically significant net differences in HDL and triglycerides, but not 
weight, BP, or total cholesterol. The fifth study (88), in adolescents, however, found no 
effect on weight (although, this was also true for a similar program with group sessions).
Programs in Adolescents
Two studies were conducted in adolescents. In the study by Savoye et al. (102), adolescents 
who participated in twice-a-week group sessions were significantly more likely to revert to 
normoglycemia, lose weight, and have lower FG and BP compared with a control group, but 
there was no change in lipid profile, except triglycerides. None developed diabetes during 
the 6 month follow-up period. The study by Patrick et al. (88) evaluated three different 
programs (web, web and text message, and web and group session programs) and reported 
no difference in weight loss compared with a control group after 6 and 12 months. The study 
did not report incident diabetes or FG outcomes.
Discussion
Across the wide spectrum of D&PA programs, there is strong evidence of effectiveness in 
reducing new-onset diabetes Across 16 studies, participants in D&PA programs were 
consistently about 40% less likely to develop diabetes, but this outcome was evaluated in 
only a minority (30%) of studies. D&PA programs also increase the likelihood of reverting 
to normoglycemia and they improve diabetes and cardiometabolic risk factors, including 
overweight, high blood glucose, high blood pressure, and abnormal lipid profile. The 
effectiveness of these programs on cardiovascular disease, diabetes-related complications, 
and death is yet to be determined since few studies reported these outcomes.
During protocol development, we searched Medline and the Cochrane Database of 
Systematic Reviews for pertinent systematic reviews; none was found that was sufficiently 
up-to-date and that evaluated the breadth of outcomes and range of analyses evaluated in the 
current review. The most comprehensive review was a health technology assessment by 
Gillett et al. whose search was conducted in 2011 (121), but also included diet or exercise 
Balk et al. Page 9
Ann Intern Med. Author manuscript; available in PMC 2016 March 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
interventions (not in combination); nine randomized trials were included. An updated search 
found three similar, but more restrictive reviews published since 2013. They focused on 
narrower subsets of studies in adults. Schellenberg et al. included nine randomized trial of 
D&PA programs that had at least one other component (122). Dunkley et al. included 25 
studies (11 randomized trials) of D&PA programs that explicitly translated previous efficacy 
trials into the community settings (123), but included studies of a broader population (e.g., 
obese or sedentary). Aguiar et al. included only eight studies (5 randomized trials) of D&PA 
interventions that included both aerobic and resistance training (124). Both reviews found 
similar effects on weight loss, and the latter also on FG. In meta-regression, Dunkley et al. 
found larger changes in weight with better alignment with lifestyle intervention attributes 
(123).
The evidence suggests that higher intensity programs lead to greater weight loss and 
reduction in new-onset diabetes. While evaluated programs were too different from each 
other to draw firm conclusions about the unique contributions of specific program 
components, results from 12 studies that directly compared programs showed that people 
who received more intensive programs (based on features such as number of sessions, 
individual sessions, and additional personnel) lost more weight and were less likely to 
develop diabetes. The studies that compared programs with controls had very similar effects 
on diabetes risk across studies; therefore, no differences based on differences in their 
programs could be ascertained. However, across all studies, programs that provided 
individual (vs. group) diet sessions resulted in greater reductions in FG, as did programs that 
used diet counselors (vs. no diet counselors). Programs based on DPP or DPS (which were 
more intensive than many other programs) resulted in greater weight loss. More information 
on virtual delivery will be useful to increase the reach of effective D&PA programs.
Based on evidence from two of the larger studies (the U.S. DPP and the Finnish DPS), 
findings appear to be applicable to wide populations (in Western countries) across race and 
ethnicity, socioeconomic status, risk factor status, and other demographic features. With the 
exception of programs in two studies, all programs were applied in adults; therefore, our 
results may not apply in children and adolescents. However, it is likely that the benefit of 
D&PA programs is applicable to younger individuals at risk for type 2 diabetes because the 
disease mechanisms are shared between adults and children. Although most cases of 
diabetes in children are due to type 1 diabetes, nearly all cases of diabetes that develop from 
pre-diabetes (being at increased risk of diabetes) are due to type 2 diabetes. Key aspects of 
the pathophysiology of type 2 diabetes are similar in individuals of all ages; thus, the 
programs are likely to be effective regardless of age, assuming the programs are effective at 
changing children’s diet and physical activity. The one in-person program conducted in 
adolescents was similarly effective as programs conducted in adults; however, the other 
study in adolescents of various virtual programs found no effect on weight.
Additional studies comparing D&PA programs to usual care (no program), will likely not 
change the overall conclusion about the D&PA programs’ effectiveness with the exception 
of programs for children and adolescents and, possibly, in specific populations or settings 
where there are gaps in data. However, there are several areas that would benefit from future 
research in this area. Because the available programs were highly heterogeneous with many 
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features included, all of which likely interacted with each other, we were unable to explain 
the observed heterogeneity by whether programs included specific features. Furthermore, 
despite often protracted descriptions of the interventions, articles often failed to clearly 
identify who led the interventions, what the goals were, or to provide other details to one to 
reproduce the intervention. Future studies that compare specific program features are needed 
to clarify which features (eg, individual versus group sessions, few versus many sessions, 
differently trained counselors) optimize the effectiveness of the programs and which are less 
critical. It is also unclear what is the most effective way to structure the maintenance phase 
to help program participants maintain their improvements. Additionally, with the 
proliferation of mobile devices and applications, the effectiveness of virtual programs needs 
to be further investigated. Importantly, long-term follow-up of (existing) community-based 
programs are needed to evaluate the durability of the programs’ effects and their effects on 
clinical outcomes. Although this review did not specifically address participant attrition, a 
better understanding is needed of what typical attrition rates are, to understand the reasons 
program participants drop out, and to develop methods to retain them in the programs.
In conclusion, combined D&PA promotion programs are effective for people at increased 
risk of type 2 diabetes for reducing new-onset diabetes, increasing reversion to 
normoglycemia and improving diabetes and cardiometabolic risk factors. Programs are 
effective across a wide range of program features but more intensive interventions appear to 
be more effective. Further research is needed to discern which specific program features are 
most important.
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Figure 1. 
Random-effects model meta-analysis of RR of incident diabetes in at-risk participants in 
combined diet and physical activity promotion programs vs. usual care.
For the meta-analysis of the overall summary risk ratio (RR) of incident diabetes (black 
diamond), the longest duration of follow-up from each study was used, as indicated by the 
asterisks and the grey boxes which correspond to the weight of each study in the overall 
meta-analysis. Subgroup meta-analyses by follow-up time (open diamonds) were conducted 
for time points with data from at least three studies. CI = confidence interval, Cx = control 
(usual care), D&PA = combined diet and physical activity promotion program, PHet = Chi-
squared P value of heterogeneity, RD = risk difference, RR = risk ratio.
* Included in overall meta-analysis.
† To avoid biased meta-analyses due to including correlated analyses, this comparison 
between the lower intensity intervention and control was excluded from meta-analysis.
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Figure 2. 
Random-effects model meta-analysis of RR of reversion to normoglycemia in at-risk 
participants in combined diet and physical activity promotion programs vs. usual care.
See Figure 1 legend.
* Included in overall meta-analysis.
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Figure 3. 
Random-effects model meta-analysis of net percent change in weight (from baseline) in at-
risk participants in combined diet and physical activity promotion programs vs. usual care.
See Figure 1 legend. Study data closest to 1 year follow-up were included in the overall 
meta-analysis.
* Included in overall meta-analysis.
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† To avoid biased meta-analyses due to including correlated analyses, this comparison 
between the lower intensity intervention and control was excluded from meta-analysis.
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Table 1
Characteristics of Combined Diet and Physical Activity Promotion Programs
Category, No. Programs/Studies Characteristic Median (IQI) [Range] or No. of Programs (%)
No. sessions, 67 programs Core 10 (6–16) [0*–72]
Maintenance, 28 programs 6 (1.5–12) [0*–24]
Total 15 (6.5–24.5) [0*–72]]
Program duration, 67 programs Core 6 mo (5–12) [1–60]
Maintenance, 28 programs 12 (7–18) [4–68]
Total 12 mo (10–27) [3–72]
Program design†, 67 programs Nominally based on DPP or DPS 27 (40%)
Weight loss goal†, 67 programs 42 (63%)
Diet intervention†, 67 programs Individual sessions 40 (60%)
Group sessions 41 (61%)
Individual and group 24 (36%)
Individually tailored diet plan 16 (24%)
Diet goal 19 (28%)
Diet counselor 29 (43%)
Physical activity intervention†, 67 programs Individual sessions 41 (61%)
Group sessions 39 (58%)
Individual and group 24 (36%)
Individually tailored exercise plan 23 (34%)
Exercise goal 32 (48%)
Exercise counselor 18 (27%)
Counselors†, 51 programs Dietitian 37 (73%)
Exercise therapist 26 (51%)
Nurse 15 (29%)
Layperson 13 (25%)
Physician 8 (16%)
Diabetes educator 3 (6%)
Country, 53 studies U.S. / Canada 22 (42%)
Western Europe/Australia 22 (42%)
Japan 3 (6%)
Middle income‡ 6 (11%)
Setting, 41 studies Community 12 (29%)
Healthcare system 25 (61%)
Worksite 0
Multiple 4 (10%)
Location, 53 studies Urban 25 (47%)
Regional 21 (40%)
Suburban 2 (4%)
Rural 1 (2%)
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Category, No. Programs/Studies Characteristic Median (IQI) [Range] or No. of Programs (%)
Mixed 4 (8%)
DPP = U.S. Diabetes Prevention Program Trial, DPS = Finnish Diabetes Prevention Study, IQI = interquartile interval, mo = months.
*
In some programs, the contacts were by telephone, email, internet, or video only.
†
Likely underestimates due to inadequate or unclear reporting in articles.
‡
India 3, Brazil 1, China 1, Pakistan 1.
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Table 2
Characteristics of Study Participants
Category, No. Studies Characteristic Median (IQI) [Range] or No. of Studies (%)
Eligibility criteria, 53 studies Prediabetes, IGT, or IFG 30 (57%)
 By ADA/WHO criteria 21 (40%)
At increased risk for DM (by risk score) 12 (23%)
Prediabetes or at increased risk for DM 4 (8%)
Prediabetes or at increased risk for CVD 4 (8%)
Metabolic syndrome ± prediabetes 3 (6%)
Body weight, 47 studies Mean BMI, kg/m2 31.2 (28.1, 33.6) [23.8, 39.7]
Hypertension, 4 studies % participants 34.5 [30.6, 50]
Female, 39 studies % participants 65.3 (50.3, 73.9) [13.5, 90.5]
Age, 39 studies† Mean years 53.6 (48, 57) [43.1, 65.0]
Ethnicity‡
 13 studies White, % participants 74 [18, 89]
 10 studies Black/African-American, % participants 18 [12, 39]
 8 studies Hispanic/Latino, % participants 13 [3, 38]
 5 studies East Asian, % participants 100
 6 studies Southeast Asian, % participants 100
 4 studies Asian/Pacific Islander, % participants 4, 5, 15, 17§
 4 studies Native American, % participants 1, 3, 6, 100§
Education
 9 studies <High school (or equivalent), % participants 14 (11, 33) [5, 64]
 20 studies High school (or some college), % participants 30 (21, 48) [10, 69]
 11 studies Bachelors degree (or equivalent), % participants 28 (20, 37) [14, 52]
 4 studies Graduate degree (or equivalent), % participants 13, 15, 16, 35§
DPP = U.S. Diabetes Prevention Program Trial, DPS = Finnish Diabetes Prevention Study, IQI = interquartile interval, mo = months.
*
In some programs, the maintenance period contacts were by telephone or email only.
†
Excluding 2 studies in adolescents.
‡
Excluding counts of studies with 0% of an ethnicity.
§
List of percentages among relevant studies.
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